Climb Bio (CLYM) EBIT (2020 - 2026)
Climb Bio (CLYM) reported EBIT of -$15.2 million for Q1 2026, up 33.92% on a YoY basis from -$11.4 million in Q1 2025, and up 21.17% quarter-over-quarter from -$19.3 million in Q4 2025.
Climb Bio (CLYM) EBIT (2020 - 2026) Analysis & Trends
Climb Bio has reported EBIT for 7 years, with the latest figure at -$15.2 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 33.92% year-over-year to -$15.2 million; the trailing twelve-month figure through Mar 2026 stood at -$60.1 million (up 41.12% YoY), and the FY2025 full-year result was -$67.9 million, up 17.24% from the prior year.
- EBIT for Q1 2026 stood at -$15.2 million, up from -$19.3 million in the prior quarter.
- The five-year high for EBIT was -$3.0 million in Q1 2024, with the low at -$56.4 million in Q2 2024.
- Historically, EBIT has averaged -$14.7 million across 5 years, with a median of -$11.7 million in 2024.
- The largest YoY upside for EBIT was 87.18% in 2024 against a maximum downside of 739.62% in 2024.
- Climb Bio's EBIT stood at -$9.6 million in 2022, then surged by 46.39% to -$5.1 million in 2023, then tumbled by 113.02% to -$10.9 million in 2024, then slumped by 76.85% to -$19.3 million in 2025, then climbed by 21.17% to -$15.2 million in 2026.
- The last three EBIT figures came in at -$15.2 million (Q1 2026), -$19.3 million (Q4 2025), and -$14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -65.83 Mn |
| 10 | Climb Bio | 774.84 Mn | 774.84 Mn | - | -15.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.21 Mn |
| Dec 31, 2025 | -19.30 Mn |
| Sep 30, 2025 | -14.89 Mn |
| Jun 30, 2025 | -10.68 Mn |
| Mar 31, 2025 | -23.02 Mn |
| Dec 31, 2024 | -10.91 Mn |
| Sep 30, 2024 | -11.73 Mn |
| Jun 30, 2024 | -56.37 Mn |
| Mar 31, 2024 | -3.01 Mn |
| Dec 31, 2023 | -5.12 Mn |
| Sep 30, 2023 | -5.00 Mn |
| Jun 30, 2023 | -6.71 Mn |
| Mar 31, 2023 | -23.44 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | -8.75 Mn |
| Jun 30, 2022 | -13.70 Mn |
| Mar 31, 2022 | -13.13 Mn |
| Dec 31, 2021 | -10.70 Mn |
| Sep 30, 2021 | -9.38 Mn |
| Jun 30, 2021 | -8.71 Mn |